TheStreet reiterated their buy rating on shares of Celgene Corp. (NASDAQ:CELG) in a research report sent to investors on Friday morning, AnalystRatingsNetwork.com reports.
“Celgene Corporation (CELG) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.,” TheStreet’s analyst commented.
Celgene Corp. (NASDAQ:CELG) opened at 169.81 on Friday. Celgene Corp. has a one year low of $81.33 and a one year high of $173.80. The stock’s 50-day moving average is $163.9 and its 200-day moving average is $147.3. The company has a market cap of $69.973 billion and a price-to-earnings ratio of 49.51.
Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter last year, the company posted $1.29 earnings per share. Celgene Corp.’s revenue was up 18.0% compared to the same quarter last year. Analysts expect that Celgene Corp. will post $6.00 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. to $196.00 in a research note to investors on Thursday, December 19th. They now have a buy rating on the stock. Separately, analysts at Credit Suisse upgraded shares of Celgene Corp. from a neutral rating to an outperform rating in a research note to investors on Tuesday, December 10th. They now have a $210.00 price target on the stock, up previously from $165.00. Finally, analysts at Citigroup Inc. reiterated a buy rating on shares of Celgene Corp. in a research note to investors on Friday, December 6th. They now have a $204.00 price target on the stock, up previously from $182.00. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have given a buy rating to the company. Celgene Corp. has an average rating of Buy and a consensus price target of $165.48.
In other Celgene Corp. news, Insider Lawrence Stein unloaded 12,062 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $168.19, for a total transaction of $2,028,707.78. Following the completion of the transaction, the insider now directly owns 50 shares in the company, valued at approximately $8,410. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.